CG Oncology, Inc. filed a Form 8-K on November 16, 2026, disclosing topline data from its Phase 3 PIVOT-006 registrational trial of cretostimogene in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, along with updated BLA submission timelines.

Key Highlights

  • Primary endpoint met: PIVOT-006 achieved its primary endpoint with a statistically significant improvement versus the control arm, according to the filing.
  • 68% reduction in recurrence risk: Cretostimogene demonstrated a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001) compared with the control arm.
  • Median follow-up of 17 months: Data was measured as of October 26, 2026.
  • No Grade 3 or greater TRAEs: The filing reported no treatment-related adverse events of Grade 3 or higher and no treatment-related discontinuations.
  • BCG-unresponsive BLA submission planned for March 2027: The company anticipates completing submission of its BLA for BCG-unresponsive NMIBC, expanded to include high-grade papillary-only disease, in March 2027.
  • Second BLA planned for Q2 2027: A separate BLA for intermediate-risk and high-grade Ta NMIBC is planned for submission in the second quarter of 2027.
  • No approved adjuvant options in target population: The filing states there are currently no FDA-approved adjuvant treatment options for the approximately 50,000 patients in this population.

CG Oncology Reports PIVOT-006 Topline Data and Updated BLA Timelines for Cretostimogene

According to the filing, CG Oncology (NASDAQ:CGON) announced on November 16, 2026, that its Phase 3 PIVOT-006 registrational trial evaluating adjuvant intravesical cretostimogene met its primary endpoint. The trial enrolled patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer measuring 3 cm or less following complete tumor resection. The company disclosed that cretostimogene produced a 68% reduction in the risk of recurrence compared with the control arm, with a hazard ratio of 0.32 (95% CI: 0.23, 0.45; p<0.0001) and a median follow-up of 17 months as of October 26, 2026.

The filing stated that cretostimogene "was generally well tolerated, with safety results consistent with those reported in previous studies." The company reported no Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations. The filing also noted that there are currently no FDA-approved adjuvant treatment options for the approximately 50,000 patients in this NMIBC population.

CG Oncology also disclosed updated BLA submission timelines. The company stated it anticipates completing its BLA submission for BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors, and now also including BCG-unresponsive high-grade papillary-only disease, in March 2027. A second BLA for the intermediate-risk and high-grade Ta NMIBC indication is planned for the second quarter of 2027. The filing cautions that forward-looking statements, including BLA timelines and clinical interpretations, are subject to risks and uncertainties described in the company's regulatory filings, and actual results may differ.

What Was Disclosed

CG Oncology's Form 8-K disclosed topline Phase 3 PIVOT-006 trial results for cretostimogene in NMIBC, reporting a 68% recurrence risk reduction and no Grade 3 or higher treatment-related adverse events, along with updated BLA submission timelines for March 2027 and Q2 2027.